Insider Selling: NIOX Group (LON:NIOX) Insider Sells 3,824 Shares of Company Stock

Key Points

• Insider Sarah Duncan sold 3,824 NIOX Group shares on October 27 at an average price of GBX 80, for proceeds of £3,059.20.
• NIOX shares traded at GBX 64.60 on Wednesday, below the insider sale price; the stock’s 52-week range is GBX 53.84 to GBX 80.
• The company reported quarterly earnings of GBX 1.41 per share, with a 14.74% net margin and 10.01% return on equity.

NIOX Group Plc (LON:NIOX - Get Free Report) insider Sarah Duncan sold 3,824 shares of the business's stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of GBX 80, for a total transaction of £3,059.20.

NIOX Group Stock Performance

NIOX traded up GBX 0.20 on Wednesday, hitting GBX 64.60. 281,066 shares of the company's stock were exchanged, compared to its average volume of 902,221. The firm has a market cap of £271.88 million, a PE ratio of 39.63 and a beta of 0.92. NIOX Group Plc has a twelve month low of GBX 53.84 and a twelve month high of GBX 80. The stock has a fifty day moving average of GBX 67.34 and a two-hundred day moving average of GBX 63.13. The company has a current ratio of 4.60, a quick ratio of 1.94 and a debt-to-equity ratio of 1.06.

NIOX Group (LON:NIOX - Get Free Report) last issued its earnings results on Wednesday, September 30th. The company reported GBX 1.41 earnings per share (EPS) for the quarter. NIOX Group had a net margin of 14.74% and a return on equity of 10.01%. On average, research analysts anticipate that NIOX Group Plc will post 1.17 earnings per share for the current fiscal year.

NIOX Group Company Profile

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange ticker: NIOX, the company operates internationally, serving healthcare professionals in over 50 countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.